S&P Futures
3,917.75 +20.00 (+0.51%) Dow Futures
31,315.00 +113.00 (+0.36%) Nasdaq Futures
11,976.50 +98.25 (+0.83%) Russell 2000 Futures
1,787.80 +12.90 (+0.73%) Crude Oil
111.65 -0.56 (-0.50%) Gold
1,846.80 +5.60 (+0.30%)
Supernus Pharmaceuticals, Inc. (SUPN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 26.95 |
| Open | 26.68 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 26.50 - 27.59 |
| 52 Week Range | 23.15 - 34.50 |
| Volume | |
| Avg. Volume | 496,396 |
| Market Cap | 1.448B |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | 20.63 |
| EPS (TTM) | 1.31 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SUPN
Related Research
- Supernus Pharmaceuticals, Inc.SUPN: Raising target price to $29.00SUPERNUS PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat2 days agoArgus Research
- GlobeNewswire
Supernus Announces First Quarter 2022 Financial Results
First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectivelyFirst quarter 2022 GAAP operating income of $2.0 million; first quarter 2022 non-GAAP operating income of $28.0 millionU.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adultsQelbree continued its growth trajectory, with 47,324 prescriptions in first quarter
- GlobeNewswire
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2022 after the market closes on Monday, May 9, 2022. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call
- American City Business Journals
This MoCo biotech’s ADHD drug just earned FDA approval — this time, for adults
Rockville’s Supernus Pharmaceuticals Inc. has earned regulatory approval for its attention deficit hyperactivity disorder drug for adults, more than a year after landing the green light to commercialize the product for kids. The Food and Drug Administration has given its nod to Qelbree as a treatment for ADHD in adults ages 18 and older, Supernus said Monday. The expansion of the approval, already in effect for children and adolescents ages 6 to 17, creates a new option for 16 million U.S. patients with ADHD.
